Vancomycin resistance: are there better glycopeptides coming? (Q37340562)

19 August 2017

1 reference

title

Vancomycin resistance: are there better glycopeptides coming? (English)

1 reference

19 August 2017

1 reference

Peter K Linden

1

1 reference

19 August 2017

publication date

1 December 2008

1 reference

Expert Review of Anti-infective Therapy

19 August 2017

published in

1 reference

19 August 2017

volume

6

1 reference

19 August 2017

issue

6

1 reference

19 August 2017

page(s)

917-928

1 reference

Symposium on antimicrobial agents--Part XII. Vancomycin

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Safety and efficacy of glycopeptide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Ramoplanin: a lipoglycodepsipeptide antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Excessive use of vancomycin: a successful intervention strategy at an academic medical center

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Emergence of vancomycin resistance in coagulase-negative staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Vancomycin resistance in staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Intrapulmonary pharmacokinetics of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Penetration of vancomycin into human lung tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

The pharmacokinetic and pharmacodynamic properties of vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Vancomycin resistance in gram-positive cocci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Vancomycin-resistant staphylococci and enterococci: epidemiology and control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Successful treatment of right-sided prosthetic valve endocarditis due to methicillin-resistant teicoplanin-heteroresistant Staphylococcus aureus with linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Synergy of Vancomycin plus Cefazolin or Cephalothin against Methicillin-Resistant Staphylococcus epidermidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Staphylococcus epidermidis with intermediate resistance to vancomycin: elusive phenotype or laboratory artifact?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

New antimicrobial agents as therapy for resistant gram-positive cocci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Intra-hospital dissemination of quinupristin/dalfopristin- and vancomycin-resistant Enterococcus faecium in a paediatric ward of a German hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Clinical characteristics of linezolid-resistant Staphylococcus aureus infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Review of dalbavancin, a novel semisynthetic lipoglycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Glycopeptide antibiotics: from conventional molecules to new derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

21 January 2018

Glycopeptide derivatives

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Antistaphylococcal activity of dalbavancin, an experimental glycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Glycopeptides: Update on an old successful antibiotic class

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Telavancin: a novel lipoglycopeptide for serious gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

In vitro activity of TD-6424 against Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

Glycopeptides in clinical development: pharmacological profile and clinical perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.917

21 January 2018

Identifiers

DOI

10.1586/14787210.6.6.917

1 reference

19 August 2017

1 reference